Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4Endocrine 3

Conditions

Melanoma 36Neoplasm Metastasis 12Neoplasms 10Colorectal Neoplasms 5Thyroid Neoplasms 4Thyroid Cancer, Papillary 4Multiple Myeloma 4Leukemia, Hairy Cell 4Hematologic Neoplasms 4Skin Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Thyroid Carcinoma, Anaplastic 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Brain Neoplasms 2Thyroid cancer, follicular 1Thrombocytosis 1Sarcoma, Clear Cell 1Sarcoma 1Relapsed Pediatric Solid Tumor 1Rare Tumour 1Rare Tumor 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Iodine-131 14trametinib 9dabrafenib 9Thyroidectomy 9Surgical Procedures, Operative 9lenvatinib 8Thyroxine 8Magnetic Resonance Spectroscopy 8pembrolizumab 7Paclitaxel 7anlotinib 6Thyrotropin Alfa 6selpercatinib 5Sorafenib 5Saline Solution 5Radiofrequency Ablation 5Everolimus 5pazopanib 4Vemurafenib 4Sunitinib 4Radiotherapy 4Nivolumab 4Fluorodeoxyglucose F18 4Dexmedetomidine 4Cyclophosphamide 4Biopsy, Fine-Needle 4Biopsy 4Bevacizumab 4apatinib 3Triiodothyronine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Thyroid Neoplasms × Vemurafenib × Clear all
NCT01709292 2026-04-16

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
24 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
50 enrolled
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
8 enrolled 8 charts
EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT02145143 2025-06-18

Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Completed
12 enrolled
Head & Neck

Thyroid Neoplasms, Heterotaxy Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡